By Michele Maatouk
Date: Tuesday 31 Mar 2026
(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
| Currency | US Dollars |
| Share Price | $ 252.29 |
| Change Today | $ -0.97 |
| % Change | -0.38 % |
| 52 Week High | $256.47 |
| 52 Week Low | $159.56 |
| Volume | 164,992 |
| Shares Issued | 146.80m |
| Market Cap | $37,035m |
| RiskGrade | 259 |
| Strong Buy | 11 |
| Buy | 10 |
| Neutral | 11 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 33 |

| Time | Volume / Share Price |
| 12:04 | 107 @ $252.29 |
| 12:04 | 100 @ $252.15 |
| 12:04 | 100 @ $252.20 |
| 12:04 | 200 @ $252.20 |
| 12:04 | 100 @ $252.18 |
You are here: research